Cryo-Cell International has signed an exclusive agreement with China’s S-Evans Bioscience (SEB) to market and manufacture the proprietary C’elle(SM) menstrual stem cell technology.

The partnership will allow SEB exclusive rights to the processing and storage of menstrual stem cells throughout mainland China, enabling the company to conduct scientific research using C’elle(SM).

The exclusive license agreement with SEB will provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells.

S-Evans Biosciences CEO Dr Charlie Xiang said that stem cell research and development is well recognised and fast emerging in China.

“SEB believes that the innovative C’elle technology may provide women with the opportunity to collect and cryopreserve their own stem cells, which have considerable potential to be used in future therapies and are a non-controversial to harvest,” Xiang said.

The C’elle service is based on Cryo-Cell’s patent-pending IP technology portfolio, introduced in November 2007, which allows women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future use by the donor or close relatives in a similar way to how umbilical cord blood stem cells are used.

The Chinese government has recently announced a new healthcare reform plan that is expected to allocate considerable resources towards stem cell research and development.